Cancer Trials & Tribulations: Combinations Are Easier Said Than Done
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Combinations of checkpoint inhibitors and targeted drugs are said to hold the key to better, more durable results in the future. But recent studies highlighted some big challenges, like unexpected toxicities, prompting a call for more preclinical research to better predict winning combinations.